Association of rheumatoid arthritis-related autoantibodies with pulmonary function test abnormalities in a rheumatoid arthritis registry
We investigated whether rheumatoid arthritis (RA)-related autoantibodies were associated with abnormalities on pulmonary function tests (PFTs).
We studied RA serostatus and PFT abnormalities within a RA registry. RA serostatus was assessed by research assays for cyclic citrullinated peptide (CCP) and rheumatoid factor (RF). Outcomes were abnormalities on clinically indicated PFTs, including restriction, obstruction, and diffusion abnormality. Logistic regression was used to obtain ORs and 95% CIs for the PFT abnormalities by RA serologic phenotypes independent of lifestyle and RA characteristics.
Among 1272 analyzed subjects, mean age was 56.3 years (SD 14.1), 82.2% were female, and 69.5% were seropositive. There were 100 subjects with abnormal PFTs. Compared with seronegativity, seropositivity was associated with increased odds of any PFT abnormality (multivariable OR 2.29, 95% CI 1.30–4.03). When analyzing type of PFT abnormality, seropositivity was also associated with restriction, obstruction, and diffusion abnormalities; multivariable ORs were 2.48 (95% CI 1.26–4.87), 3.12 (95% CI 1.28–7.61), and 2.30 (95% CI 1.09–4.83), respectively. When analyzing by CCP and RF status, the associations were stronger for RF+ than for CCP+ (any PFT abnormality OR 1.99, 95% CI 1.21–3.27 for RF+ vs. RF−; OR 1.67, 95% CI 1.03–2.69 for CCP+ vs. CCP−) with a dose effect of higher RF titer increasing odds for each PFT abnormality (p for trend < 0.05).
• Due to the known excess pulmonary morbidity/mortality in RA, we studied the relationship of rheumatoid arthritis (RA)-related autoantibodies with pulmonary function test (PFT) abnormalities using a large RA registry.
• We evaluated whether presence and levels of cyclic citrullinated peptide (CCP) and rheumatoid factor (RF) were associated with restriction, obstruction, and diffusion abnormalities on PFTs among 1272 subjects with RA.
• Seropositivity was associated with two-fold increased risk for any PFT abnormality, independent of confounders including smoking. Higher titers of RF conferred greatest risk for all PFT outcomes: obstruction, restriction, and diffusion abnormality.
• These results provide evidence that patients with RA should be closely monitored for pulmonary involvement, particularly those with high-titer RF seropositivity.
KeywordsCCP Pulmonary disease RF Rheumatoid arthritis Serostatus
The authors thank Elizabeth W. Karlson, MD, MS for her support and guidance. We thank Vivi Feathers for the assistance in data management and statistical analysis. We thank the dedicated RA participants and staff of the Brigham Rheumatoid Arthritis Sequential Study (BRASS) at Brigham and Women’s Hospital for their continued participation in this longitudinal research study.
All authors were involved in drafting the article or revising it critically for important intellectual contact, and all authors approved the final version to be published. Huang, He, Shadick, and Sparks were involved in the study conception and design; Huang, Zaccardelli, Marshall, Friedlander, Blaustein, Smith, Cui, Iannaccone, Mahmoud, Weinblatt, Shadick and Sparks in acquisition of data; and Huang, He, Doyle, Zaccardelli, Marshall, Friedlander, Cui, Iannaccone, Mahmoud, Weinblatt, Dellaripa, Shadick and Sparks in data analysis and interpretation. Dr. Huang had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
This work was supported by the Rheumatology Research Foundation K Supplement Award and the National Institutes of Health (grant numbers K23 AR069688, K23 HL119558, R03 AR075886, L30 AR066953, R01 AR049880, P30 AR070253, and P30 AR072577). The Brigham Rheumatoid Arthritis Sequential Study is funded by grants from Bristol-Myers Squibb, Crescendo Bioscience, and Sanofi/Regeneron. The funders had no role in study design, data collection, analysis, decision to publish, or preparation of the manuscript. The content is solely the responsibility of the authors and does not necessarily represent the official views of Harvard University, its affiliated academic health care centers, or the National Institutes of Health.
Compliance with ethical standards
The study protocol and informed consent document were reviewed and approved by the Partners HealthCare Institutional Review Board. All subjects provided written informed consent before participating in the BRASS registry.
Conflict of interest
Tracy J. Doyle reports research funding from Bristol-Myers Squibb and involvement in a clinical trial funded by Genentech. Paul F. Dellaripa reports research funding from Bristol-Myers Squibb and involvement in a clinical trial funded by Genentech. Michael E. Weinblatt reports research grants from Amgen, Crescendo Bioscience, Sanofi/Regeneron, and Bristol-Myers Squibb; consultancy to Abbvie, Amgen, Bristol-Myers Squibb, Canfite, Corrona, Crescendo Bioscience, GlaxoSmithKline, Gilead, Lilly, Lycera, Merck, Novartis, Pfizer, Roche, Samsung, Set Point, and Scipher; and stock options in Lycera, Canfite, Scipher, Vorso, and Inmedix. Nancy A. Shadick reports research funding from Bristol-Myers Squibb, Crescendo Biosciences, Sanofi Regeneron, and Mallinckrodt; and consultancy to Bristol-Myers Squibb. Jeffrey A. Sparks reports research funding from Bristol-Myers Squibb and Amgen and consultancy to Optum.
- 9.Kelly CA, Saravanan V, Nisar M, Arthanari S, Woodhead FA, Price-Forbes AN, Dawson J, Sathi N, Ahmad Y, Koduri G, Young A, on behalf of the British Rheumatoid Interstitial Lung (BRILL) Network (2014) Rheumatoid arthritis-related interstitial lung disease: associations, prognostic factors and physiological and radiological characteristics--a large multicentre UK study. Rheumatology (Oxford) 53(9):1676–1682CrossRefGoogle Scholar
- 19.Iannaccone CK, Lee YC, Cui J, Frits ML, Glass RJ, Plenge RM, Solomon DH, Weinblatt ME, Shadick NA (2011) Using genetic and clinical data to understand response to disease-modifying anti-rheumatic drug therapy: data from the Brigham and Women’s Hospital Rheumatoid Arthritis Sequential Study. Rheumatology (Oxford) 50(1):40–46CrossRefGoogle Scholar
- 20.Doyle TJ, Dellaripa PF, Batra K, Frits ML, Iannaccone CK, Hatabu H, Nishino M, Weinblatt ME, Ascherman DP, Washko GR, Hunninghake GM, Choi AMK, Shadick NA, Rosas IO (2014) Functional impact of a spectrum of interstitial lung abnormalities in rheumatoid arthritis. Chest. 146(1):41–50CrossRefGoogle Scholar
- 21.Doyle TJ, Patel AS, Hatabu H, Nishino M, Wu G, Osorio JC, Golzarri MF, Traslosheros A, Chu SG, Frits ML, Iannaccone CK, Koontz D, Fuhrman C, Weinblatt ME, el-Chemaly SY, Washko GR, Hunninghake GM, Choi AMK, Dellaripa PF, Oddis CV, Shadick NA, Ascherman DP, Rosas IO (2015) Detection of rheumatoid arthritis-interstitial lung disease is enhanced by serum biomarkers. Am J Respir Crit Care Med 191(12):1403–1412CrossRefGoogle Scholar
- 23.Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, Chen R, Decramer M, Fabbri LM, Frith P, Halpin DMG, López Varela MV, Nishimura M, Roche N, Rodriguez-Roisin R, Sin DD, Singh D, Stockley R, Vestbo J, Wedzicha JA, Agustí A (2017) Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report. GOLD executive summary. Am J Respir Crit Care Med 195(5):557–582CrossRefGoogle Scholar
- 24.Johnson JD, Theurer WM (2014) A stepwise approach to the interpretation of pulmonary function tests. Am Fam Physician 89(5):359–366Google Scholar
- 25.Radner H, Yoshida K, Mjaavatten MD, Aletaha D, Frits M, Lu B, Iannaccone C, Shadick N, Weinblatt M, Hmamouchi I, Dougados M, Smolen JS, Solomon DH (2015) Development of a multimorbidity index: impact on quality of life using a rheumatoid arthritis cohort. Semin Arthritis Rheum 45(2):167–173CrossRefGoogle Scholar
- 27.Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL (1995) Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38(1):44–48CrossRefGoogle Scholar
- 36.Fischer A, Solomon JJ, du Bois RM, Deane KD, Olson AL, Fernandez-Perez ER, Huie TJ, Stevens AD, Gill MB, Rabinovitch AM, Lynch DA, Burns DA, Pineiro IS, Groshong SD, Duarte Achcar RD, Brown KK, Martin RJ, Swigris JJ (2012) Lung disease with anti-CCP antibodies but not rheumatoid arthritis or connective tissue disease. Respir Med 106(7):1040–1047CrossRefGoogle Scholar
- 38.Ford JA, Liu X, Marshall AA, Zaccardelli A, Prado MG, Wiyarand C, Lu B, Karlson EW, Schur PH, Deane KD, Sparks JA (2018) Impact of cyclic citrullinated peptide antibody level on progression to rheumatoid arthritis in clinically tested CCP-positive patients without RA. Arthritis Care Res (Hoboken)Google Scholar
- 40.Karlson EW, Chibnik LB, Cui J, Plenge RM, Glass RJ, Maher NE, Parker A, Roubenoff R, Izmailova E, Coblyn JS, Weinblatt ME, Shadick NA (2008) Associations between human leukocyte antigen, PTPN22, CTLA4 genotypes and rheumatoid arthritis phenotypes of autoantibody status, age at diagnosis and erosions in a large cohort study. Ann Rheum Dis 67(3):358–363CrossRefGoogle Scholar
- 42.van der Helm-van Mil AH, Verpoort KN, Breedveld FC, Huizinga TW, Toes RE, de Vries RR (2006) The HLA-DRB1 shared epitope alleles are primarily a risk factor for anti-cyclic citrullinated peptide antibodies and are not an independent risk factor for development of rheumatoid arthritis. Arthritis Rheum 54(4):1117–1121CrossRefGoogle Scholar
- 43.Klareskog L, Stolt P, Lundberg K, Kallberg H, Bengtsson C, Grunewald J et al (2006) A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum 54(1):38–46CrossRefGoogle Scholar